Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
Telomir Pharmaceuticals (NASDAQ:TELO) has announced a significant breakthrough in stabilizing both Silver(I) and Silver(II) ions using Telomir-1, making them biologically compatible for medical applications. This achievement addresses a major limitation in silver-based medical treatments.
The breakthrough opens opportunities in the silver wound dressings market, valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030. The broader antimicrobial coatings market is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, with a 14.2% CAGR.
Silver(II) offers enhanced healing properties compared to Silver(I), including stronger antimicrobial action, accelerated wound healing, and anti-inflammatory properties. The stabilization through Telomir-1 enables applications in burn care, chronic wound management, and medical device coatings.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato una significativa innovazione nella stabilizzazione degli ioni Silver(I) e Silver(II) utilizzando Telomir-1, rendendoli biologicamente compatibili per applicazioni mediche. Questo risultato affronta una importante limitazione nei trattamenti medici a base di argento.
Questa innovazione apre opportunità nel mercato dei bendaggi per ferite in argento, valutato 1,03 miliardi di dollari nel 2024 e previsto raggiungere 1,36 miliardi di dollari entro il 2030. Si prevede che il mercato più ampio dei rivestimenti antimicrobici cresca da 11,65 miliardi di dollari nel 2024 a 33,7 miliardi di dollari entro il 2031, con un tasso di crescita annuale composto (CAGR) del 14,2%.
Il Silver(II) offre proprietà di guarigione migliorate rispetto al Silver(I), inclusa una maggiore azione antimicrobica, un'accelerazione nella guarigione delle ferite e proprietà antinfiammatorie. La stabilizzazione attraverso Telomir-1 consente applicazioni nella cura delle ustioni, nella gestione delle ferite croniche e nei rivestimenti per dispositivi medici.
Telomir Pharmaceuticals (NASDAQ:TELO) ha anunciado un avance significativo en la estabilización de los iones Silver(I) y Silver(II) utilizando Telomir-1, haciéndolos biológicamente compatibles para aplicaciones médicas. Este logro aborda una limitación importante en los tratamientos médicos basados en plata.
El avance abre oportunidades en el mercado de vendajes para heridas de plata, valorado en 1,03 mil millones de dólares en 2024 y se espera que alcance 1,36 mil millones de dólares para 2030. Se proyecta que el mercado más amplio de recubrimientos antimicrobianos crezca de 11,65 mil millones de dólares en 2024 a 33,7 mil millones de dólares para 2031, con una tasa de crecimiento anual compuesta (CAGR) del 14,2%.
El Silver(II) ofrece propiedades de curación mejoradas en comparación con el Silver(I), incluyendo una acción antimicrobiana más fuerte, una aceleración en la curación de heridas y propiedades antiinflamatorias. La estabilización a través de Telomir-1 permite aplicaciones en el cuidado de quemaduras, manejo de heridas crónicas y recubrimientos de dispositivos médicos.
텔로미르 제약 (NASDAQ:TELO)은 텔로미르-1을 사용하여 실버(I) 및 실버(II) 이온을 안정화하는 데 있어 중요한 돌파구를 발표하였으며, 이를 통해 의료 응용을 위한 생물학적 호환성을 확보했습니다. 이 성과는 은 기반 의료 치료의 주요 한계를 해결합니다.
이 돌파구는 은 상처 드레싱 시장에 기회를 열어주며, 이 시장은 2024년에 10억 3천만 달러로 평가되며 2030년까지 13억 6천만 달러에 이를 것으로 예상됩니다. 더 넓은 항균 코팅 시장은 2024년 116억 5천만 달러에서 2031년까지 337억 달러로 성장할 것으로 예상되며, 연평균 성장률(CAGR)은 14.2%입니다.
실버(II)는 실버(I)보다 강화된 치유 특성을 제공하며, 여기에는 강력한 항균 작용, 상처 치유 가속화 및 항염증 특성이 포함됩니다. 텔로미르-1을 통한 안정화는 화상 치료, 만성 상처 관리 및 의료 기기 코팅에 응용할 수 있게 합니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé une avancée significative dans la stabilisation des ions Silver(I) et Silver(II) grâce à Telomir-1, les rendant biologiquement compatibles pour des applications médicales. Cette réalisation répond à une limitation majeure des traitements médicaux à base d'argent.
Cette avancée ouvre des opportunités sur le marché des pansements pour blessures en argent, évalué à 1,03 milliard de dollars en 2024 et prévu pour atteindre 1,36 milliard de dollars d'ici 2030. Le marché plus large des revêtements antimicrobiens devrait passer de 11,65 milliards de dollars en 2024 à 33,7 milliards de dollars d'ici 2031, avec un taux de croissance annuel composé (CAGR) de 14,2%.
Le Silver(II) offre des propriétés de guérison améliorées par rapport au Silver(I), y compris une action antimicrobienne plus forte, une guérison des blessures accélérée et des propriétés anti-inflammatoires. La stabilisation grâce à Telomir-1 permet des applications dans les soins des brûlures, la gestion des plaies chroniques et les revêtements de dispositifs médicaux.
Telomir Pharmaceuticals (NASDAQ:TELO) hat einen bedeutenden Durchbruch bei der Stabilisierung von Silber(I)- und Silber(II)-Ionen mit Telomir-1 bekannt gegeben, wodurch diese biologisch kompatibel für medizinische Anwendungen werden. Dieser Erfolg adressiert eine wesentliche Einschränkung in silberbasierten medizinischen Behandlungen.
Der Durchbruch eröffnet Möglichkeiten im Markt für Silberwundverbände, der 2024 auf 1,03 Milliarden Dollar geschätzt wird und bis 2030 auf 1,36 Milliarden Dollar anwachsen soll. Der breitere Markt für antimikrobielle Beschichtungen wird voraussichtlich von 11,65 Milliarden Dollar im Jahr 2024 auf 33,7 Milliarden Dollar bis 2031 wachsen, mit einer jährlichen Wachstumsrate (CAGR) von 14,2%.
Silber(II) bietet im Vergleich zu Silber(I) verbesserte Heilungseigenschaften, einschließlich einer stärkeren antimikrobiellen Wirkung, beschleunigter Wundheilung und entzündungshemmenden Eigenschaften. Die Stabilisierung durch Telomir-1 ermöglicht Anwendungen in der Brandwundenversorgung, im Management chronischer Wunden und in medizinischen Geräuschbeschichtungen.
- Breakthrough in stabilizing both Silver(I) and Silver(II) ions in biologically compatible form
- Access to silver wound dressings market ($1.03B in 2024, growing to $1.36B by 2030)
- Entry into antimicrobial coatings market ($11.65B in 2024, growing to $33.7B by 2031)
- Enhanced therapeutic potential with stronger antimicrobial and healing properties
- None.
Insights
The stabilization of Silver(II) ions represents a remarkable technical breakthrough with far-reaching implications for the medical industry. While silver-based treatments are not new, Telomir's innovation addresses a fundamental limitation that has plagued the field for decades - the inability to harness the superior oxidative and antimicrobial properties of Ag2+ ions in a biologically compatible form.
The technical achievement is particularly significant for three reasons:
- The stabilization occurs in a biologically compatible environment, unlike previous attempts that relied on toxic chemical stabilizers
- The technology enables controlled release mechanisms, important for medical applications
- The dual stabilization of both Ag+ and Ag2+ ions provides versatility in treatment applications
- Regulatory pathway clarity - while topical applications may face lower barriers, medical device coatings will require extensive safety validation
- Manufacturing scalability - consistent production of stabilized Ag2+ compounds at commercial scale presents technical challenges
- Pricing strategy - premium pricing potential exists due to enhanced efficacy, but must be balanced against existing silver-based solutions
From a market perspective, this positions Telomir to potentially capture significant share in both the $1.03 billion wound care market and the broader $11.65 billion antimicrobial coatings sector. The technology's applications in medical device coatings, particularly for implants and catheters, could provide recurring revenue streams through licensing agreements with device manufacturers.
However, several critical factors will determine commercial success:
The technology's potential extends beyond immediate applications. The ability to stabilize highly reactive ions in biological environments could lead to breakthroughs in drug delivery systems and create new possibilities for treating antibiotic-resistant infections, a growing concern in healthcare settings.
MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.
Silver-based medical treatments represent a rapidly growing market, with the silver wound dressings segment valued at
Why Silver(II) Has Enhanced Healing Properties
Silver has long been used in medicine for its antimicrobial effects, particularly in wound care, burn treatment, and medical coatings. Silver(II) (Ag²⁺) is a rare oxidation state of silver, as silver typically exists in the +1-oxidation state Silver(I) (Ag⁺). While Silver(I) compounds have demonstrated strong antibacterial activity, Silver(II) offers significantly enhanced healing potential due to its greater oxidative capacity, broader bactericidal activity, and potential role in tissue regeneration.
More Potent Antimicrobial Action - Silver(II) is a stronger oxidizing agent than Silver(I), meaning it disrupts bacterial cell membranes, proteins, and DNA more aggressively, leading to rapid bacterial cell death. Unlike Silver(I), which primarily interacts with bacterial surfaces, Silver(II) generates reactive oxygen species (ROS) that can penetrate biofilms and kill even antibiotic-resistant bacteria.
Accelerated Wound Healing - Silver(II) has been observed to stimulate fibroblast activity and scaring processes, which are essential for collagen production and tissue repair. Additionally, its ability to upregulate vascular endothelial growth factor (VEGF) supports the formation of new blood vessels, increasing oxygen and nutrient delivery to damaged tissues.
Anti-Inflammatory and Immune-Modulating Properties - Silver(II) may reduce excessive inflammation by suppressing pro-inflammatory cytokines that contribute to delayed healing in chronic wounds. Studies suggest that Silver(II) may also help balance immune responses, promoting a more favorable healing environment.
Despite these advantages, Silver(II) has not been effectively used in medicine due to its extreme instability and rapid degradation-until now.
Solving the Challenge of Silver(II) Stability
While some chemical methods-such as fluorosulfates, tetraazamacrocyclic ligands, and heterocyclic amines-have briefly stabilized Silver(II) in controlled lab conditions, these approaches are not viable for biological applications due to toxicity, instability, and lack of controlled release.
Telomir-1 has the potential to be the first known biologically compatible carrier capable of stabilizing Silver(II) for medical applications, overcoming a key limitation that has historically prevented its use in healthcare.
Expanding Medical Applications with Telomir-1
By the potential to stabilizing both Silver(I) and Silver(II) in controlled-release formulations, Telomir-1 may enable new and more effective treatments in key medical areas, including:
Burn and wound care - Silver-based dressings are widely used to prevent infections in severe burns and open wounds. A stabilized Silver(II) formulation could enhance antimicrobial efficacy and accelerate healing.
Chronic wound management - Diabetic ulcers, MRSA skin infections, and post-surgical wounds could benefit from a longer-lasting, more potent silver-based therapy.
Medical device coatings - Silver-infused hospital surfaces, implants, and catheters could provide sustained antimicrobial protection, reducing the risk of hospital-acquired infections.
Unlocking a Multi-Billion-Dollar Market
"The ability to stabilize Silver(II) in a controlled and biologically relevant way is a game-changing scientific achievement," said Erez Aminov, Chairman & CEO of Telomir. "This discovery extends Telomir-1's capabilities beyond age-related conditions and into high-value medical applications that were previously unattainable. Given the size and rapid growth of the silver-based medical market, Silver(II) complexed-Telomir-1 could become a key player in advancing next-generation therapeutics for infection control, wound healing, and more."
Scientific Validation from Telomir's Experts
"The ability to stabilize Silver(II) has been considered nearly impossible due to its extreme reactivity and rapid degradation," said Dr. Itzchak Angel, Ph.D., Chief Scientific Advisor of Telomir. "What we have achieved with Telomir-1 represents a significant leap forward in material science and medical chemistry. By successfully stabilizing Silver(II) in a biologically compatible form, we may have unlocked the potential for a new class of therapeutics capable of transforming topical antimicrobial treatments, accelerating wound healing, and enhancing infection control. This is more than just a scientific breakthrough-it is the first step toward potentially reshaping how silver-based medicine is used in modern healthcare."
Dr. Alex Weisman, Ph.D. in Chemistry and Scientific Advisor at Telomir, added: "Silver has long been recognized for its antimicrobial properties, but until now, the industry has been limited to working with Silver(I) due to the extreme instability of Silver(II). Telomir-1's ability to complex with Silver(II) provides an unprecedented solution, allowing us to harness the full potential of Silver(II) in a controlled, biologically safe manner. This opens potential new avenues for silver-based therapeutics that were previously out of reach."
Telomir is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
References:
Grand View Research (2024). "Silver Wound Dressing Market Size & Share Report." Retrieved from: https://www.grandviewresearch.com/industry-analysis/silver-wound-dressing-market
Verified Market Research (2024). "Antimicrobial Coatings Market Report." Retrieved from: https://www.verifiedmarketresearch.com/product/antimicrobial-coatings-market/
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market potential for Telomir's (TELO) silver stabilization breakthrough?
How does Telomir-1's Silver(II) stabilization improve upon existing silver treatments?
What medical applications will Telomir's (TELO) silver stabilization technology target?
What makes Telomir's (TELO) February 2025 silver stabilization breakthrough significant?
